 |
 |
Due to the recent discussion, I felt it beneficial to repost this message. ---------- > From: Michael Rezak <[log in to unmask]> > To: [log in to unmask] > Subject: Riluzole Study > Date: Friday, May 14, 1999 1:41 PM > > Hi Everyone, > > There has been some discussion on the List lately regarding the > investigational drug riluzole which is currently in FDA trials across the > U.S. If any one is located within reasonable commuting distance from our > movement disorders center, we are currently looking for participants for > this study. We have submitted the requirements below for anyone who has > interest in participating. > > > Study of the Effectiveness of an Investigational Medication in Slowing the > Progression of Parkinson's Disease > > Physicians at Glenbrook and Evanston Hospitals in Glenview, IL have been > chosen to study the effectiveness of an investigational medication > (riluzole) versus a placebo in slowing the progression of Parkinson's > disease in untreated, early diagnosed patients. > > We are seeking volunteers to take part who are between 40-80 years old, > have had symptoms of Parkinson's disease for less than three years and have > not had symptomatic medication treatment for more than three months over > the past year. > > The clinical trial lasts 26 months and will require 17 visits to our office > at Glenbrook Hospital in Glenview. If you qualify, all study-related care > including physical examinations, laboratory services, and study medication > will be provided to you at no charge. > > This study will help determine if this investigational treatment slows the > deterioration process of Parkinson's disease and consequently slows the > overall progression of the disease. > > For more information about this research study, please contact: > > Sandy Vergenz, R.N., B.S.N. or Paula Parks, B.S. > Glenbrook Hospital > 2100 Pfingsten Road > Glenview, IL 60025 > Telephone: (847) 657-5672 > [log in to unmask] >